AVITA Medical, Inc.
Business
AVITA Medical is a therapeutic acute wound care company delivering proprietary technologies to optimize wound healing and recovery in burns, traumatic injuries, and surgical repairs. Its portfolio includes RECELL, an autologous cell harvesting device for thermal burns and full-thickness skin defects; Cohealyx, a collagen-based dermal matrix; and PermeaDerm, a biosynthetic wound matrix distributed under exclusive agreements. The company commercializes primarily through direct sales in U.S. burn and trauma centers and surgical settings, with international expansion via third-party distributors in approved markets.
Summary from 10-K filed 2026-02-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Sales revenue | 71 | 64 | 50 | — | — | |
| Lease revenue | 731,000 | 358,000 | — | — | — | |
| Total revenues | 72 | 64 | 50 | 34 | 29 | |
| Cost of sales | −13 | −9 | −8 | −6 | −6 | |
| Gross profit | 59 | 55 | 42 | 28 | 23 | |
| Sales and marketing | −53 | −58 | −37 | −22 | −15 | |
| General and administrative | −27 | −33 | −28 | −23 | −22 | |
| Research and development | −21 | −20 | −21 | −14 | −15 | |
| Total operating expenses | −101 | −112 | −86 | −59 | −52 | |
| Operating loss | −43 | −57 | −43 | −28 | −27 | |
| Interest expense | −5 | −5 | −1 | −16,000 | −22,000 | |
| Other (expense) income, net | −1 | 163,000 | 8 | 892,000 | — | |
| Loss before income taxes | −49 | −62 | −35 | −27 | −27 | |
| Income tax expense | −11,000 | −54,000 | −66,000 | −36,000 | −38,000 | |
| Net loss | −49 | −62 | −35 | −27 | −27 | |
| Basic (per share) | −1.74 | −2.39 | −1.4 | −1.07 | −1.17 | |
| Diluted (per share) | −1.74 | −2.39 | −1.4 | −1.07 | −1.17 | |
| Basic (shares) | 28 | 26 | 25 | 25 | 23 | |
| Diluted (shares) | 28 | 26 | 25 | 25 | 23 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 10 | 14 | 22 | 18 | 56 | |
| Marketable securities | 8 | 22 | 67 | 61 | 30 | |
| Accounts receivable, net | 9 | 12 | 8 | 4 | 3 | |
| Prepaids and other current assets | 1 | 2 | 2 | 2 | 1 | |
| Inventory | 7 | 7 | 6 | 2 | 2 | |
| Total current assets | 35 | 57 | 104 | 87 | 92 | |
| Plant and equipment, net | 9 | 10 | 2 | 1 | 1 | |
| Operating lease right-of-use assets | 3 | 4 | 2 | 851,000 | 2 | |
| "Corporate-owned life insurance (""COLI"") asset" | 3 | 3 | 2 | 1 | 304,000 | |
| Intangible assets, net | 6 | 6 | 487,000 | 465,000 | 443,000 | |
| Other long-term assets | 612,000 | 546,000 | 355,000 | 122,000 | 638,000 | |
| Total assets | 56 | 80 | 112 | 98 | 116 | |
| Accounts payable and accrued liabilities | 9 | 6 | 4 | 3 | 3 | |
| Accrued wages and fringe benefits | 8 | 10 | 8 | 7 | 5 | |
| Loan facility | 43 | 0 | — | — | — | |
| "Current non-qualified deferred compensation (""NQDC"") liability" | 276,000 | 2 | 168,000 | 78,000 | — | |
| Other current liabilities | 3 | 1 | 1 | 990,000 | 1 | |
| Total current liabilities | 63 | 20 | 13 | 11 | 9 | |
| Loan facility - long-term | 0 | 42 | 40 | — | — | |
| Non-qualified deferred compensation liability | 4 | 3 | 4 | 1 | 262,000 | |
| Contract liabilities | 290,000 | 324,000 | 357,000 | 698,000 | 952,000 | |
| Operating lease liabilities, long term | 2 | 3 | 2 | 306,000 | 918,000 | |
| Contingent liability, long-term | 3 | 3 | — | — | — | |
| Warrant liabilities | 1 | 3 | — | — | — | |
| Total liabilities | 73 | 75 | 62 | 13 | 11 | |
| Non-qualified deferred compensation plan share awards | 0 | 244,000 | 693,000 | 557,000 | — | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 30,571,662 and 26,354,042, shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | |
| Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | — | |
| Company common stock held by the non-qualified deferred compensation plan | −1 | −1 | −1 | −127,000 | — | |
| Additional paid-in capital | 394 | 368 | 350 | 340 | 332 | |
| Accumulated other comprehensive loss | −1 | −2 | −2 | 8 | 8 | |
| Accumulated deficit | −408 | −360 | −298 | −263 | −236 | |
| Total stockholders' equity (deficit) | −17 | 4 | 49 | 85 | 105 | |
| Total liabilities, non-qualified deferred compensation plan share awards and stockholders' equity (deficit) | 56 | 80 | 112 | 98 | 116 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Fair value of common stock issued related to loan amendment | 2 | — | — | — | — | |
| Change in fair value of long-term debt | 1 | 2 | 2 | — | — | |
| Change in fair value of warrant liability | −2 | 274,000 | 733,000 | — | — | |
| Depreciation and amortization | 2 | 1 | 632,000 | 568,000 | 715,000 | |
| Stock-based compensation | 10 | 13 | 8 | 7 | 6 | |
| Non-cash lease expense | 890,000 | 843,000 | 748,000 | 692,000 | 591,000 | |
| Loss on fixed asset disposal | 595,000 | 107,000 | 83,000 | 3,000 | 130,000 | |
| Loss on patent disposal | 11,000 | 16,000 | 4,000 | — | — | |
| Remeasurement and foreign currency transaction loss | 17,000 | 21,000 | 37,000 | −85,000 | 228,000 | |
| Excess and obsolete inventory related charges | 810,000 | 487,000 | 221,000 | 375,000 | 226,000 | |
| Provision for credit losses | −10,000 | 23,000 | 24,000 | — | — | |
| Amortization of premium of marketable securities | −308,000 | −2 | −1 | −281,000 | — | |
| Non-cash changes in the fair value of NQDC plan | −1 | 402,000 | 856,000 | 38,000 | — | |
| Trade and other receivables | 4 | −4 | −4 | −395,000 | −1 | |
| Prepaids and other current assets | 766,000 | −371,000 | −451,000 | −366,000 | −342,000 | |
| Inventory | −468,000 | −2 | −4 | −371,000 | −745,000 | |
| Operating lease liability | −905,000 | −906,000 | −713,000 | −720,000 | −594,000 | |
| "Corporate-owned life insurance (""COLI"") asset" | 406,000 | −271,000 | −1 | −1 | — | |
| Other long-term assets | −65,000 | −191,000 | −233,000 | 178,000 | −889,000 | |
| Accounts payable and accrued expenses | 3 | 340,000 | 809,000 | 282,000 | −1 | |
| Accrued wages and fringe benefits | −3 | 2 | 1 | 1 | 493,000 | |
| Current non-qualified deferred compensation liability | −2 | 2 | −2 | — | — | |
| Other current liabilities | −81,000 | 122,000 | 266,000 | −92,000 | 155,000 | |
| Non-qualified deferred compensation plan liability | 2 | −1 | 2 | 994,000 | — | |
| Contract liabilities | −33,000 | −33,000 | −341,000 | −254,000 | 640,000 | |
| Net cash used in operating activities | −31 | −49 | −38 | −19 | −26 | |
| Purchase of marketable securities | −13 | −25 | −79 | −74 | — | |
| Maturities of marketable securities | 28 | 71 | 79 | 56 | — | |
| Purchase of plant and equipment | −1 | −9 | −1 | −452,000 | −894,000 | |
| Capitalized software development costs | −635,000 | 0 | — | — | — | |
| Patent filing fees | −99,000 | −162,000 | −66,000 | −73,000 | −280,000 | |
| Net cash provided by investing activities | 12 | 37 | 2 | −19 | −1 | |
| Proceeds from private placement of common stock | 15 | — | — | — | 69 | |
| Proceeds from exercise of stock options | 407,000 | 2 | 957,000 | 900,000 | 63,000 | |
| "Employee stock purchase plan (""ESPP"") purchases" | 795,000 | 1 | 655,000 | — | — | |
| Net cash provided by financing activities | 15 | 4 | 40 | 900,000 | 64 | |
| Net decrease in cash and cash equivalents | −4 | −8 | 4 | −38 | 37 | |
| Income taxes paid during the period | 15,000 | 41,000 | 44,000 | 17,000 | — | |
| Interest paid during the period | 5 | 5 | 1 | 15,000 | 3,000 | |
| Intangible asset purchase not yet paid | — | 5 | — | — | — | |
| Capital expenditures not yet paid | 17,000 | 115,000 | 6,000 | 33,000 | 20,000 | |
| Right-of-use-asset obtained in exchange for lease liabilities | 235,000 | 2 | 2 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is AVITA Medical, Inc.'s CIK number?
AVITA Medical, Inc.'s SEC CIK number is 0001762303 (1762303). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find AVITA Medical, Inc.'s SEC filings?
All of AVITA Medical, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did AVITA Medical, Inc. last report earnings?
AVITA Medical, Inc. (RCEL) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-224022). This is AVITA Medical, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is AVITA Medical, Inc.'s most recent earnings 8-K?
AVITA Medical, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-224022. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View AVITA Medical, Inc.'s latest earnings 8-K →
Look up any company's CIK number →